These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23312237)
21. [Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma]. Voilliot-Trotot C; Granel-Brocard F; Geoffrois L; Tréchot P; Nguyen-Thi P; Schmutz JL; Barbaud A Ann Dermatol Venereol; 2013 May; 140(5):353-62. PubMed ID: 23663707 [TBL] [Abstract][Full Text] [Related]
22. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682 [TBL] [Abstract][Full Text] [Related]
23. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial. Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376 [TBL] [Abstract][Full Text] [Related]
24. The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer--a phase I trial. Schwarzlose-Schwarck S; Scholz CW; Regierer AC; Martus P; Neumann C; Habbel P; Liu H; Zang C; Schefe JH; Schulz CO; Possinger K; Eucker J Anticancer Res; 2012 Aug; 32(8):3435-41. PubMed ID: 22843927 [TBL] [Abstract][Full Text] [Related]
25. Current phase II clinical data for ridaforolimus in cancer. Spreafico A; Mackay HJ Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772 [TBL] [Abstract][Full Text] [Related]
26. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor. Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575 [TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Raymond E; Alexandre J; Faivre S; Vera K; Materman E; Boni J; Leister C; Korth-Bradley J; Hanauske A; Armand JP J Clin Oncol; 2004 Jun; 22(12):2336-47. PubMed ID: 15136596 [TBL] [Abstract][Full Text] [Related]
28. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa. Sonis S; Andreotta PW; Lyng G Oral Dis; 2017 Apr; 23(3):347-352. PubMed ID: 27896917 [TBL] [Abstract][Full Text] [Related]
30. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Peterson DE; O'Shaughnessy JA; Rugo HS; Elad S; Schubert MM; Viet CT; Campbell-Baird C; Hronek J; Seery V; Divers J; Glaspy J; Schmidt BL; Meiller TF Cancer Med; 2016 Aug; 5(8):1897-907. PubMed ID: 27334013 [TBL] [Abstract][Full Text] [Related]
31. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. Demetri GD; Chawla SP; Ray-Coquard I; Le Cesne A; Staddon AP; Milhem MM; Penel N; Riedel RF; Bui-Nguyen B; Cranmer LD; Reichardt P; Bompas E; Alcindor T; Rushing D; Song Y; Lee RM; Ebbinghaus S; Eid JE; Loewy JW; Haluska FG; Dodion PF; Blay JY J Clin Oncol; 2013 Jul; 31(19):2485-92. PubMed ID: 23715582 [TBL] [Abstract][Full Text] [Related]
32. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800 [TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631 [TBL] [Abstract][Full Text] [Related]
34. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients. Nashan B Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498 [TBL] [Abstract][Full Text] [Related]